









Markets
/
Stocks
/
nasdaq-cdxs
/

Codexis Inc

CDXS

2.450USD

-0.040-1.61%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

221.12MMarket Cap

LossP/E TTM



Codexis Inc

2.450

-0.040-1.61%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance and strong technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

108 / 506

Overall Ranking

211 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Buy

Current Rating

7.083

Target Price

+184.47%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.

Growing

The company is in a growing phase, with the latest annual income totaling USD 59.34M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 94.32.

Fairly Valued

The company’s latest PE is -3.04, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 75.27M shares, decreasing 8.29% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 4.59M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.67.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.98, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 15.33M, representing a year-over-year increase of 92.10%, while its net profit experienced a year-over-year increase of 41.67%.

Score

Industry at a Glance

Previous score

5.98

Change



Financials

6.63

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.30

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.31

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -3.09, which is -16.79% below the recent high of -2.57 and -15.86% above the recent low of -3.58.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 108/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Codexis Inc is 7.00, with a high of 11.00 and a low of 3.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Buy

Current Rating

7.083

Target Price

+184.47%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Codexis Inc

CDXS

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.14, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 2.94 and the support level at 2.17, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.14

Change

-0.09

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.008

Neutral

RSI(14)

42.543

Neutral

STOCH(KDJ)(9,3,3)

54.695

Neutral

ATR(14)

0.119

Low Volatility

CCI(14)

11.647

Neutral

Williams %R

65.591

Sell

TRIX(12,20)

-0.666

Sell

StochRSI(14)

80.023

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

2.444

Buy

MA10

2.442

Buy

MA20

2.525

Sell

MA50

2.760

Sell

MA100

2.600

Sell

MA200

3.216

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 90.86%, representing a quarter-over-quarter increase of 8.28%. The largest institutional shareholder is The Vanguard, holding a total of 4.59M shares, representing 5.08% of shares outstanding, with 7.32% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Opaleye Management Inc.

12.24M

+2.08%

Casdin Capital, LLC

8.10M

BlackRock Institutional Trust Company, N.A.

6.23M

+0.44%

The Vanguard Group, Inc.

Star Investors

4.72M

+5.85%

Fidelity Management & Research Company LLC

4.31M

+1.18%

abrdn Inc.

606.29K

+19.20%

Nantahala Capital Management, LLC

2.83M

-0.39%

Telemark Asset Management, LLC

3.00M

Columbia Threadneedle Investments (US)

2.53M

+5.63%

Geode Capital Management, L.L.C.

1.93M

+3.76%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.12, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 2.52. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.